Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020008209
Abstract: This Phase 2 study evaluated isatuximab as monotherapy or combined with dexamethasone in relapsed/refractory multiple myeloma (RRMM). Patients had RRMM refractory to an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) or had received ≥3… read more here.
Keywords: relapsed refractory; isatuximab monotherapy; refractory multiple; monotherapy combined ... See more keywords